Bioinformatics analysis of the expression of HOXC13 and its role in the prognosis of breast cancer

CHANGYOU LI*, JUNWEI CUI*, LI ZOU, LIZHANG ZHU and WEI WEI

Department of Breast Surgery, Shenzhen Hospital, Peking University, Shenzhen, Guangdong 518036, P.R. China

Received April 13, 2019; Accepted October 10, 2019

DOI: 10.3892/ol.2019.11140

Abstract. The homeobox (HOX) genes, a class of transcription factors, are known to promote embryonic development and induce tumor formation. To date, the HOXA and HOXB gene families have been reported to be associated with breast cancer. However, the expression and exact role of homeobox C13 (HOXC13) in breast cancer has not yet been investigated. In the present study, the HOXC13 expression in human breast cancer was evaluated using the Oncomine database and Cancer Cell Line Encyclopedia (CCLE). Next, the Gene expression-based Outcome for Breast cancer online database, cBioportal, University of California Santa Cruz Xena browser and bc-GenExMinerv were used to explore the specific expression of HOXC13 in breast cancer. The methylation and mutation status of HOXC13 in breast cancer was then validated using the CCLE and cBioportal databases. Finally, the co-expression of HOX transcript antisense RNA (HOTAIR) and HOXC13 in breast cancer were analyzed and their impact on clinical prognosis determined. It was found that the expression of HOXC13 was high in breast cancer compared with other types of cancer, such as gastric cancer and colon cancer. Following co-expression analysis, a significant positive association was identified between HOTAIR and HOXC13. An association between HOTAIR and HOXC13, and lymph node and distant metastasis recurrence was also revealed during the development of breast cancer. Of note, survival analysis showed that high expression of HOTAIR and HOXC13 predicted poor prognosis. These findings revealed that HOXC13 plays an important role in the progression of breast cancer. However, the specific mechanism needs to be confirmed by subsequent experiments.

Introduction

Breast cancer, the most common type of cancer in women, presents a challenge for global research (1). Molecular research on breast cancer was at a bottleneck, until the identification of a correlation between BRCA1/2 DNA repair associated and breast cancer was reported and marked great progress in the research, treatment and prognosis of breast cancer (2,3). Following this, genetic susceptibility has become the focus of breast cancer research (4). However, in the context of big data, with the development of high-throughput sequencing technology, it is not difficult to find susceptibility genes.

The Homeobox (HOX) genes is a large class of transcription factors that play an important role in embryogenesis and oncogenesis, as well as the distribution of fat and hair in body (5-7). In humans, the HOX gene family contains 39 HOX genes located on 4 different chromosomes (7p15, 17q21.2, 12q13 and 2q31) (8). The 39 HOX genes are divided into 4 clusters (HOXA, HOXB, HOXC and HOXD) (9). Each HOX gene contains a well-conserved DNA sequence, known as the homeobox (10). The unique expression pattern, including mutation, and dependent mechanism of the HOX genes regulates, to some extent, the embryonic development of vertebrates (11,12). When HOX protein expression is upregulated, it may lead to cancer (5). It has also been reported that the HOXC gene family is highly expressed in certain solid tumors, including lung, prostate and colon cancer (13,14). The HOXA and HOXB gene families have a similar expression in breast cancer, which is derived from the ectoderm. Whether the expression level of the HOX gene follows the origin of the germ layer in cancer requires further investigation. A study has reported that HOXC13, a member of the HOX gene family, is highly expressed in the MCF-7 cell line (15). Thus, the present study aimed to explore the expression and significance of HOXC13 in breast cancer.

In the present study, the Oncomine and tumor public databases (bc-GenExMinerv 4.2; GOBO database; CCLE) were used to analyze the expression level of HOXC13 in different types of cancer including breast cancer. HOXC13 was then further investigated in breast cancer. The expression and co-expression of HOXC13 in breast cancer was re-analyzed using the University of California, Santa Cruz (UCSC) cancer genomics browser. Finally, the clinical significance of HOXC13 in breast cancer was further explored.
Materials and methods

Oncomine database verification. The Oncomine (www.oncomine.org) database is a public bioinformatics database containing gene expression data set that has become an industry-standard tool cited in >1,100 peer-reviewed journal articles (16,17). The Oncomine platform has been used as a foundation for ground-breaking discoveries with unique features that include scalability, high quality, consistency and standardized analysis (18). In order to screen out the most meaningful RNA probes, the paired Student's t-test was used to generate P-values to compare expression differences between cancer and healthy adjacent non-cancerous tissues. Relevant statistical indicators were used as follows: P<1x10^-4, fold change >4 and gene ranking in the top 10%. Moreover, the Oncomine database was used to explore the co-expression analysis of HOXC13 in breast cancer. The search term ‘HOXC13’ was used, followed by coexpression analysis and selecting the cancer type as breast cancer. Lastly, the database of TCGA breast was chosen. Furthermore, the same cut-off values used as aforementioned.

Cancer cell line encyclopedia (CCLE) verification. The CCLE (portals.broadinstitute.org) provides public access to genomic data, analysis and visualization for >1,100 cell lines from various tumors, such as gastric cancer cell line AGS and intestinal cancer cell line SW480 (19,20). Each gene of the human genome has multiple datasets and data identifiers, obtained by high-throughput sequencing. The 5 major dataset types are copy number, mRNA expression (Affymetrix), reverse phase protein array, reduced representation bisulfite sequencing, and mRNA expression (RNA sequencing). The expression and methylation level of HOXC13 was analyzed in each tumor cell line using CCLE, using the search term ‘HOXC13’.

Gene expression-based Outcome for Breast cancer Online (GOBO) analysis. The GOBO database (version 1.0.3; co.bmc.lu.se/gobo/gsa_celllines.pl) is a user-friendly public database. It allows for rapid assessment of gene expression levels, identification of co-expressed genes and association with outcome for single genes, gene sets or gene signatures in an 1,881-sample breast cancer dataset (21). The most important functionality of the GOBO database is the possibility of investigating gene expression levels in breast cancer subgroups and cell lines for gene sets (22). Breast cancer subtypes are classified into basal A, basal B and luminal in the GOBO database. A correlation map is a square table where each line and column represent a gene. Each cell represents an interaction between two genes and is colored black. (coefficient=1) to dark red (coefficient=-1). Cells from the diagonal of the correlation map represent the interaction of a gene with itself and are colored black.

cBioPortal database analysis. The public cBioPortal site (www.cbioportal.org; last entered, 28th March 2019) is hosted by the Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center. The cBioportal database has been recognized as a way to verify gene mutations (24-26). This database can also analyze gene expression in different tumors and different studies (23,27). This database has been recognized by multiple studies (26,28). The online cBioPortal for Cancer Genomics was used to provide mutations of HOXC13 (including nonstart, missense, truncation and missense) and its expression in different studies (28). The cancer types and databases used were breast (TCGA2015), breast (TCGA), breast invasive carcinoma breast (TCGA PanCan) (29-34).

Breast cancer gene-expression miner (bc-GenExMiner) analysis. bc-GenExMiner (version 4.2) is a statistical mining tool of published annotated genomic data (35,36). The statistical analyses are grouped in three modules: Expression, prognosis and correlation. The co-expression of HOXC13 in breast cancer was explored using this database; each study is validated across multiple databases to avoid discrepancies in individual databases. At the same time, the effects of HOXC13 and Hox transcript antisense RNA (HOTAIR) on the survival prognosis in breast cancer were also analyzed.

Statistical analysis. Pearson test and Spearman’s rank test were used to evaluate coexpression. The analysis criteria selected were as follows: Gene, nodal and estrogen receptor status of the cohorts to be explored, event on which survival analysis will be based and splitting criterion of median HOXC13 expression. To analyze the prognostic value of HOXC13 and HOTAIR, the patient samples are split into two groups according to the median expressions of HOXC13 and HOTAIR. The two patient cohorts were compared by a Kaplan-Meier survival plot, and the hazard ratio with 95% confidence intervals and logrank P-value are calculated. Significance was determined by the P-value provided by each database.

Results

HOXC13 mRNA expression in human cancer. HOXC13 has been proven to be highly expressed in digestive tract-derived tumors (37-39). However, to the best of our knowledge, there have been no reports on the expression of HOXC13 in breast cancer. Therefore the expression levels of HOXC13 in various human tumors from the Oncomine database and CCLE were determined. A simultaneous fold change of >4, gene rank of >10% and P<1x10^-4 was set as the threshold. To our surprise, HOXC13 was found by high-throughput sequencing and biological gene chip technology to be abnormally highly expressed in breast cancer (Fig. 1A). Only breast cancer revealed significant unique analysis in the Oncomine database when the fold change was >4.

HOXC13 mRNA expression in breast cancer. The high expression of HOXC13 in breast cancer has been preliminary
confirmed in the Oncomine database, GOBO database and CCLE. From the CCLE database, it was found that at the RNAseq level, the expression level of \( \text{HOXC13} \) in breast cancer ranked fourth and ranked first in the Affy level. However, there is no report on the specific expression of \( \text{HOXC13} \) in breast cancer. Therefore, its specific expression in various subtypes of breast cancer was further explored. \( \text{HOXC13} \) was analyzed in various tumor types via Oncomine database and GOBO database and explored \( \text{HOXC13} \) in various breast cancer cells via GOBO database and CCLE. \( \text{HOXC13} \) was found to be highly expressed in invasive and luminal-like breast cancer than in any other subtype (Figs. 2 and 3). Such expression characteristics were consistent with breast cancer cell lines and tissues (Figs. 2D and 3). Using the UCSC cancer genomics browser analysis, the heat map of the gene and exon expression of \( \text{HOXC13} \) in various subtypes of breast cancer was obtained (Fig. 4A). Furthermore, the expression of \( \text{HOXC13} \) in the different data sets, including breast (TCGA 2015), breast (TCGA), breast invasive carcinoma breast (TCGA PanCan), was explored using the cBioPortal database. The expression characteristics of breast cancer in multiple data sets such as amplification and missense mutations, were demonstrated (Fig. 4B).

\( \text{HOXC13} \) methylation and mutation in human breast cancer.

The bubble chart shows the methylation level of \( \text{HOXC13} \) in breast cancer cell lines from the CCLE (Fig. 5A). \( \text{HOXC13} \) is highly methylated at three sites (positions 54,330,731, 54,330,950 and 54,330,957) on chromosome 12 from methylation and coverage (Fig. 5A). The discovery of CpG island methylation further supported the high expression of \( \text{HOXC13} \) in breast cancer. cBioPortal was used to assess the frequency of \( \text{HOXC13} \) mutations in breast cancer (Figs. 4B and 5). \( \text{HOXC13} \) contains multiple mutations in breast cancer such as amplification, gain, missense and truncation (Fig. 5). Missense and truncation are two major forms of mutation (Fig. 5).

Co-expression of \( \text{HOXC13} \) mRNA in breast cancer.

To investigate the reason for the high expression of \( \text{HOXC13} \) in breast cancer, bc-GenExMiner version 4.2 was used to analyze the potential co-expression of \( \text{HOXC13} \) in breast cancer. It was found that \( \text{HOTAIR} \) and \( \text{HOXC13} \) are highly co-expressed in breast cancer (Fig. 6A). Furthermore, to verify the co-expression of \( \text{HOXC13} \) and \( \text{HOTAIR} \) in breast cancer, their co-expression heat maps were obtained and mined (Fig. 6B) and correlation analysis was performed using the UCSC Xena browser (Fig. 6C).
Figure 2. HOXC13 expression analysis in different breast cancer subtypes. Box plots represent the expression of HOXC13 in invasive breast cancer from the Oncomine database. (A) Invasive BC (invasive lobular breast carcinoma): $P$-value=$7.04 \times 10^{-12}$. (B) Invasive BC (invasive breast carcinoma): $P$-value=$1.05 \times 10^{-16}$. (C) Invasive BC (invasive ductal breast carcinoma): $P$-value=$2.67 \times 10^{-23}$. (D-E) Red represents breast cancer subtype basal A, gray represents breast cancer subtype basal B, and blue represents breast cancer subtype luminal. (D) Using GOBO analysis, in various subtypes of breast cancer, the HOXC13 expression was significantly higher in luminal-like breast cancer: $P=0.00017$. (E) GOBO analysis showing the expression of HOXC13 in each breast cancer cell line. BC, breast carcinoma; GOBO, Gene expression-based Outcome for Breast cancer Online; HOXC13, homeobox C13. The neve expression refers to the base two logarithm of the expression of the gene in each cell, and the neve intensity refers to the expression level of each breast cancer cell relative to the expression of the internal reference.

Figure 3. HOXC13 expression analysis in breast cancer subtypes of SCM1 subtypes. (A) The box plot of HOXC13 expression according to SCM1 subtypes from bc-GenExMiner version 4.2. (B) Group comparison in each subgroup of breast cancer, and corresponding statistical values in SCM1 subtypes. HER2, human epidermal growth factor receptor 2; Lum, luminal; HOXC13, homeobox C13; SCM, subtype clustering model.
Figure 4. Analysis of the expression of HOXCl3 in breast cancer subtypes. (A) HOXCl3 expression heatmap of each breast cancer subtype in TCGA from the University of California, Santa Cruz Xena browser. Null data indicates samples that have no gene expression data. (B) HOXCl3 expression analysis and mutation status in breast cancer using cBioPortal. HOXCl3 was significantly amplified in breast cancer subtypes, including breast invasive carcinoma. The present study included datasets on breast (TCGA2015), breast (TCGA) and breast invasive carcinoma breast (TCGA PanCan) datasets. TCGA, The Cancer Genome Atlas; RNA seq, RNA sequencing; HER2, human epidermal growth factor receptor 2; RPKM, reads per kilobase of transcript per million mapped reads; HOXCl3, homeobox C13; VUS, variants of uncertain significance; CNA, copy number alteration.

Figure 5. Methylation and mutation status of HOXCl3 in breast cancer. (A) Methylation status of HOXCl3 in breast cancer cell lines. The x-axis displays the cell line in which methylation was measured. The y-axis displays the position of the methylation data. The number before the colon is the chromosome, and the number after the colon the position. Red, orange and blue represent high, medium and low levels of methylation. The size of the bubble represents coverage. (B) Mutation status of HOXCl3 in breast cancer from cBioPortal. The mutation types include nonstart, missense and truncation, and missense is shown as 1, 2, 3 and 4. The boxes in green and red represent the open reading frame. The scale shows where the mutation site is located in the sequence. Corresponding changed protein name contains M1, S242Y, X_246splice and S242Y. The data used included studies on breast cancer (29-34).
Impact of HOXC13 and HOTAIR on the prognosis of patients with breast cancer. To verify the impact of the high expression of HOXC13 and HOTAIR on patients with breast cancer, prognostic analysis of HOXC13 and HOTAIR in breast cancer was performed and HOXC13 and HOTAIR were found to have a negative impact on the prognosis of patients with tumor and lymph node metastasis (Fig. 7).

Discussion

The mammary gland is an appendage of the ectoderm, whose formation begins during embryonic development (40). Moreover, breast cancer cells remain highly associated with ectoderm cells (41). Studies have shown that the HOX gene plays an important role in embryonic development and tumor
formation (9,42-44). However, to the best of our knowledge, no research has reported the exact role of \textit{HOXC13} in breast cancer so far.

The \textit{HOXC13} gene is considered an element of hair morphogenesis, and the \textit{HOXC13} protein is a member of the human replication complex in growing cells (45,46). This is the same for breast adenocarcinoma MCF7 lines (46). \textit{HOXC13} can promote the expression of a series of proto-oncogenes, including topoisomerase I and II, and allow these expression products to form a replication complex (47,48). Therefore, \textit{HOXC13} is involved in the development of tumors. In addition, \textit{HOXC13} increases the metastasis of ectodermal-derived melanoma (49). \textit{HOTAIR} is the product of the transcription of the HOX gene cluster antisense strand (50). \textit{HOTAIR} is transcribed from the mammalian HOXC gene cluster on chromosome 12q13.13 (51,52). \textit{HOTAIR} predicts poor prognosis in tumor cell cycle and metastasis (53). It has been reported that \textit{HOTAIR} upregulates HOX in colon cancer (39). A strong co-expression of \textit{HOTAIR} and \textit{HOXC13} was confirmed in proximal and distal colon cancer, suggesting that \textit{HOTAIR} and \textit{HOXC13} could promote tumor and lymph node metastasis (39,54-56).

In the present study, it was first identified that \textit{HOXC13} is highly expressed in breast cancer both at the cellular and tissue levels. This was a finding from the co-verification of the data from TCGA's Oncomine or GSE's bc-GenExMiner. It was found for the first time that \textit{HOXC13} is most highly expressed in luminal-like subtype of breast cancer. This laid the foundation for the future study of the relationship between \textit{HOXC13} and breast cancer surface hormone receptors (estrogen receptor and progesterone receptor). In order to explore the high expression of \textit{HOXC13} in breast cancer, its methylation and mutation status were investigated. To our surprise, three sites on chromosome 12 were found to be consistently highly methylated in different breast cancer cell lines. Certain studies have reported that HOX gene methylation regulates hereditary breast cancer (57-59). In addition, the methylation level of \textit{HOXA11} is significantly higher in breast cancer compared with that in normal tissues, and is positively associated with family history and lymph node metastasis in breast cancer (59). Furthermore,
the methylation level of HOXD13 in breast cancer is almost identical to that of HOXA11, and leads to shorter survival time (58). Therefore, the present findings and the HOX gene family have consistent trends in methylation levels and similar prognostic effects in breast cancer. However, further studies on the specific regulation mechanism of HOXC13 methylation in HOXC13 transcription is required. The present study is the first to report the mutation of HOXC13 in breast cancer. Missense may be an indispensable cause of the high expression of HOXC13 in breast cancer.

The lncRNA HOTAIR is derived from the region between HOXC11 and HOXC12 (51). It has been shown that HOXC10, HOXC11, HOXC12 and HOXC13 are adjacent to each other in the HOX gene cluster (52). Simultaneously, the HOXC distal enhancer has non-specific enhancement of HOXC10 and HOTAIR enhancer activity, promoting the HOXC10 and HOTAIR expression (60). On the other hand, specific intergenic non-coding RNAs (including HOTAIR) in the HOX loci can directly modulate the expression of the HOX gene in normal and cancer status (61). This has been confirmed in colon cancer (39,55). Therefore, the mechanism between HOXC13 and HOTAIR will be explored further in this respect.

In the present study, the co-expression of HOTAIR and HOXC13 provided a new direction for studying the function of HOTAIR in breast cancer. In addition, a study has identified through meta-analysis that HOTAIR has a statistically significant effect on lymph node and distant metastasis in various types of cancer, including breast cancer, gastric cancer and colorectal cancer, which was consistent with our conclusion (62). The present data showed that HOTAIR and HOXC13 were significantly associated with lymph node metastasis and distant metastasis recurrence. Furthermore, they were shown to have a significant impact on survival period.

In conclusion, the present study was performed using public databases and revealed the expression and clinical significance of HOXC13 in breast cancer. However, the specific interactions and mechanisms involved require further experimental verification, which will be performed in future studies.

Acknowledgements

Not applicable.

Funding

This study was supported by the Shenzhen Science and Research Innovation Foundation (grant no. JCYJ20170815090309586).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

WW contributed to the experimental design and fundraising. JWC and LZ contributed to the acquisition of data. LZZ assisted in the data processing. CL processed the data and wrote the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Barrios CH, Reinert T and Werutsky G: Global breast cancer research: Moving forward. Am Soc Clin Oncol Educ Book 38: 441-450, 2018.
2. Harbeck N and Gnant M: Breast cancer. Lancet 389: 1134-1150, 2017.
3. Nathanson KL and Domchek SM: Therapeutic approaches for women predisposed to breast cancer. Ann Rev Med 62: 295-306, 2011.
4. Rousset-Jablonksi C and Gompel A: Screening for familial cancer risk: Focus on breast cancer. Maturitas 105: 69-77, 2017.
5. Luo Z, Rhee SK and Farnham PJ: The enigmatic HOX genes: Can we crack their code? Cancers (Basel) 11: pii: E323, 2019.
6. Turcotte M, Abadi A, Peralta-Romero J, Suarez F, Reddon H, Gomez-Zamudio J, Burguete-Garcia AI, Cruz M and Meyre D: Genetic contribution to waist-to-hip ratio in Mexican children and adolescents based on 12 loci validated in European adults. Int J Obes (Lond) 43: 13-22, 2019.
7. Liu F, Chen Y, Zhu G, Hysi PG, Wu S, Adhikari K, Breslin K, Pospiech E, Hamer MA, Peng F, et al: Meta-analysis of genome-wide association studies identifies 8 novel loci involved in shape variation of human head hair. Hum Mol Genet 27: 559-575, 2018.
8. Li L, Wang Y, Song G, Zhang X, Gao S and Liu H: HOX cluster-embedded antisense long non-coding RNAs in lung cancer. Cancer Lett 450: 14-21, 2019.
9. Bhaltlekar S, Fields JZ and Boman BM: Role of HOX genes in stem cell differentiation and cancer. Stem Cells Int 2018: 3569493, 2018.
10. Vaquerizas JM, Kummerfeld SK, Teichmann SA and Luscombe NM: A census of human transcription factors: Function, expression and evolution. Nat Rev Genet 10: 252-263, 2009.
11. Gordon J: Hox genes in the pharyngeal region: How Hoxa3 controls early embryonic development of the pharyngeal organs. Int J Dev Biol 62: 775-783, 2018.
12. Mallo M: The vertebrate tail: A gene playground for evolution. Cell Mol Life Sci, Sep 26, 2019 (Epub ahead of print).
13. Bhaltlekar S, Fields JZ and Boman BM: HOX genes and their role in the development of human cancers. J Mol Med (Berl) 92: 811-823, 2014.
14. Yao Y, Luo J, Sun Q, Xu T, Sun S, Chen M, Lin X, Qian Q, Zhang Y, Cao L, et al: HOXC13 promotes proliferation of lung adenocarcinoma via modulation of CCND1 and CCNE1. Am J Cancer Res 7: 1820-1834, 2017.
15. Svingen T and Tonissen KF: Altered Hox gene expression in human skin and breast cancer cells. Cancer Biol Ther 2: 518-523, 2009.
16. Shi S and Zhang ZG: Role of Sp1 expression in gastric cancer: A meta-analysis and bioinformatics analysis. Oncol Lett 18: 4126-4135, 2019.
17. Cheng L, Shi L and Dai H: Bioinformatics prognostic biomarkers among Krüppel-like transcription factors (KLFs) in breast cancer. Cancer Biomark, Oct 12, 2019 (Epub ahead of print).
18. Yang K, Gao J and Luo M: Identification of key pathways and hub genes in basal-like breast cancer using bioinformatics analysis. Onco Targets Ther 12: 1319-1331, 2019.
19. Cheng L, Pandya PH, Liu E, Chandra P, Wang L, Murray ME, Carter J, Ferguson M, Saadatzadeh MR, Bajjani-Visheshkarai K, et al: Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma. BMC Med Genomics 12 (Suppl 1): S23, 2019.
Streit M, Gratzl S, Stitz H, Wernitznig A, Zichner T and Fernández-Nogueira P, Bragado P, Almendro V, Ametller E, Zeng, Xiao Y, Zhu J, Peng C, Liang W and Lin H: Knockdown of neurogenes proliferation of triple-negative breast cancer cells through activating CDH1/Spk2/p72kip1 pathway. Cancer Manag Res 11: 143-156, 2018.

Klonowska K, Czubak B, Wojciechowska M, Handschuh L, Zmienko A, Figlerowicz M, Dams-Kozlowska H and Kozlowski P: Oncogenic portal for the visualization and analysis of genome-wide cancer data. Oncotarget 7: 176-192, 2016.

Wen W, Gong J, Wu P, Zhao M, Wang M, Chen H and Sun J: Mutations in gliacide-associated genes may predict poor bladder cancer prognosis. FEBS Open Bio 9: 457-467, 2019.

Chen E, Qi X, Peng K, Xu X, Li W, Chen X, Tung C, Cui Y, Wang Z and Liu T: Identification of potential therapeutic targets among CXC chemokines in breast tumor microenvironment using integrative bioinformatics analysis. Cell Physiol Biochem 45: 1731-1746, 2018.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larson E, et al: The eBio cancer genomics portal: an open platform for exploring multimensional cancer genomics data. Cancer Discov 2: 401-402, 2012.

Kline CLB, Ralf MD, Lulla AR, Wagner JM, Abbosh PH, Dicker DT, Allen JE and El-Deiry WS: Role of dopamine receptors in the anticancer activity of ONC201. Neoplasia 20: 80-91, 2018.

Gao L, Akerman P, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larson E, et al: Integrative analysis of complex cancer genomes and clinical profiles using the eBioPortal. Sci Signal 6: pl1, 2013.

Sanerji S, Cibulsikis K, Rangel-Escareno C, Brown KK, Carter SL, Dicker DT, Allen JE and El-Deiry WS: Role of dopamine receptors in the anticancer activity of ONC201. Neoplasia 20: 80-91, 2018.

Banerji S, Cibulsikis K, Rangel-Escareno C, Brown KK, Carter SL, Dicker DT, Allen JE and El-Deiry WS: Role of dopamine receptors in the anticancer activity of ONC201. Neoplasia 20: 80-91, 2018.

Gao L, Akerman P, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larson E, et al: Integrative analysis of complex cancer genomes and clinical profiles using the eBioPortal. Sci Signal 6: pl1, 2013.

Sanerji S, Cibulsikis K, Rangel-Escareno C, Brown KK, Carter SL, Dicker DT, Allen JE and El-Deiry WS: Role of dopamine receptors in the anticancer activity of ONC201. Neoplasia 20: 80-91, 2018.